Publications

  1. Mehner C, Miller E, Khauv D, Nassar A, Oberg AL, Bamlet WR, Zhang L, Waldmann J, Radisky ES, Crawford HC, Radisky DC. Tumor Cell-derived MMP-3 Orchestrates Rac1b and Tissue Alterations that Promote Pancreatic Adenocarcinoma. Mol Cancer Res. 2014 May 21.
    View PubMed
  2. Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 2014 May 15; 5(9):2736-49.
    View PubMed
  3. Szabo A, Radisky ES, Sahin-Toth M. Zymogen activation confers thermodynamic stability on a key peptide bond and protects human cationic trypsin from degradation. J Biol Chem. 2014; 289(8):4753-61.
  4. Szabo A, Salameh MA, Ludwig M, Radisky ES, Sahin-Toth M. Tyrosine sulfation of human trypsin steers S2' subsite selectivity towards basic amino acids. PLoS One. 2014; 9(7):e102063. Epub 2014 Jul 10.
    View PubMed
  5. Chen F, Radisky ES, Das P, Batra J, Hata T, Hori T, Baine AM, Gardner L, Yue MY, Bu G, del Zoppo G, Patel TC, Nguyen JH. TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure. J Cereb Blood Flow Metab. 2013 Jul; 33(7):1041-9. Epub 2013 Mar 27.
    View PubMed
  6. Batra J, Szabo A, Caulfield TR, Soares AS, Sahin-Toth M, Radisky ES. Long-range electrostatic complementarity governs substrate recognition by human chymotrypsin C, a key regulator of digestive enzyme activation. J Biol Chem. 2013 Apr 5; 288(14):9848-59. Epub 2013 Feb 19.
    View PubMed
  7. Batra J, Soares AS, Mehner C, Radisky ES. Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes. PLoS One. 2013; 8(9):e75836. Epub 2013 Sep 20.
    View PubMed
  8. Salameh MA, Radisky ES. Biochemical and structural insights into mesotrypsin: an unusual human trypsin. Int J Biochem Mol Biol. 2013; 4(3):129-39. Epub 2013 Sep 13.
    View PubMed
  9. Hockla A, Miller E, Salameh MA, Copland JA, Radisky DC, Radisky ES. PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol Cancer Res. 2012 Dec; 10(12):1555-66.
    View PubMed
  10. Salameh MA, Soares AS, Alloy A, Radisky ES. Presence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitors. Protein Sci. 2012 Aug; 21(8):1103-12. Epub 2012 Jun 25.
    View PubMed
  11. Stallings-Mann ML, Waldmann J, Zhang Y, Miller E, Gauthier ML, Visscher DW, Downey GP, Radisky ES, Fields AP, Radisky DC. Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med. 2012 Jul 11; 4(142):142ra95.
    View PubMed
  12. Liu H, Radisky DC, Yang D, Xu R, Radisky ES, Bissell MJ, Bishop JM. MYC suppresses cancer metastasis by direct transcriptional silencing of alphav and beta3 integrin subunits. Nat Cell Biol. 2012 Jun; 14(6):567-74. Epub 2012 May 13.
    View PubMed
  13. Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, Radisky ES. Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem. 2012 May 4; 287(19):15935-46. Epub 2012 Mar 16.
    View PubMed
  14. Justilien V, Regala RP, Tseng IC, Walsh MP, Batra J, Radisky ES, Murray NR, Fields AP. Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One. 2012; 7(4):e35040. Epub 2012 Apr 24.
    View PubMed
  15. Batra J, Robinson J, Mehner C, Hockla A, Miller E, Radisky DC, Radisky ES. PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). PLoS One. 2012; 7(11):e50028. Epub 2012 Nov 20.
    View PubMed
  16. Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES. The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity. Biochem J. 2011 Nov 15; 440(1):95-105.
    View PubMed
  17. Szabo A, Heja D, Szakacs D, Zboray K, Kekesi KA, Radisky ES, Sahin-Toth M, Pal G. High affinity small protein inhibitors of human chymotrypsin C (CTRC) selected by phage display reveal unusual preference for P4' acidic residues. J Biol Chem. 2011 Jun 24; 286(25):22535-45. Epub 2011 Apr 22.
    View PubMed
  18. Cichon MA, Radisky ES, Radisky DC. Identifying the stroma as a critical player in radiation-induced mammary tumor development. Cancer Cell. 2011 May 17; 19(5):571-2.
    View PubMed
  19. Salameh MA, Soares AS, Navaneetham D, Sinha D, Walsh PN, Radisky ES. Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin. J Biol Chem. 2010 Nov 19; 285(47):36884-96. Epub 2010 Sep 22.
    View PubMed
  20. Hockla A, Radisky DC, Radisky ES. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat. 2010 Nov; 124(1):27-38. Epub 2009 Dec 25.
    View PubMed
  21. Orlichenko L, Geyer R, Yanagisawa M, Khauv D, Radisky ES, Anastasiadis PZ, Radisky DC. The 19-amino acid insertion in the tumor-associated splice isoform Rac1b confers specific binding to p120 catenin. J Biol Chem. 2010 Jun 18; 285(25):19153-61. Epub 2010 Apr 15.
    View PubMed
  22. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010 Jun; 15(2):201-12. Epub 2010 May 05.
    View PubMed
  23. Salameh MA, Robinson JL, Navaneetham D, Sinha D, Madden BJ, Walsh PN, Radisky ES. The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin. J Biol Chem. 2010 Jan 15; 285(3):1939-49. Epub 2009 Nov 17.
    View PubMed
  24. Chen CS, Nelson CM, Khauv D, Bennett S, Radisky ES, Hirai Y, Bissell MJ, Radisky DC. Homology with vesicle fusion mediator syntaxin-1a predicts determinants of epimorphin/syntaxin-2 function in mammary epithelial morphogenesis. J Biol Chem. 2009 Mar 13; 284(11):6877-84. Epub 2009 Jan 07.
    View PubMed
  25. Salameh MA, Soares AS, Hockla A, Radisky ES. Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin. J Biol Chem. 2008 Feb 15; 283(7):4115-23. Epub 2007 Dec 12.
    View PubMed
  26. Radisky ES, Radisky DC. Stromal induction of breast cancer: Inflammation and invasion. Rev Endocr Metab Disord. 2007 Sep; 8(3):279-87.
    View PubMed
  27. Radisky ES, Lee JM, Lu CJ, Koshland DE Jr. Insights into the serine protease mechanism from atomic resolution structures of trypsin reaction intermediates. Proc Natl Acad Sci U S A. 2006 May 2; 103(18):6835-40. Epub 2006 Apr 24.
    View PubMed
  28. Radisky ES, Lu CJ, Kwan G, Koshland DE Jr. Role of the intramolecular hydrogen bond network in the inhibitory power of chymotrypsin inhibitor 2. Biochemistry. 2005 May 10; 44(18):6823-30.
    View PubMed
  29. Radisky ES, Kwan G, Karen Lu CJ, Koshland DE Jr. Binding, proteolytic, and crystallographic analyses of mutations at the protease-inhibitor interface of the subtilisin BPN'/chymotrypsin inhibitor 2 complex. Biochemistry. 2004 Nov 2; 43(43):13648-56.
    View PubMed
  30. Radisky ES, King DS, Kwan G, Koshland DE Jr. The role of the protein core in the inhibitory power of the classic serine protease inhibitor, chymotrypsin inhibitor 2. Biochemistry. 2003 Jun 3; 42(21):6484-92.
    View PubMed
  31. Radisky ES, Koshland DE Jr. A clogged gutter mechanism for protease inhibitors. Proc Natl Acad Sci U S A. 2002 Aug 6; 99(16):10316-21. Epub 2002 Jul 25.
    View PubMed
  32. Radisky ES, Poulter CD. Squalene synthase: steady-state, pre-steady-state, and isotope-trapping studies. Biochemistry. 2000 Feb 22; 39(7):1748-60.
    View PubMed
  33. Wu Z, Demma M, Strickland CL, Radisky ES, Poulter CD, Le HV, Windsor WT. Farnesyl protein transferase: identification of K164 alpha and Y300 beta as catalytic residues by mutagenesis and kinetic studies. Biochemistry. 1999 Aug 31; 38(35):11239-49.
    View PubMed
  34. Ajioka RS, Jorde LB, Gruen JR, Yu P, Dimitrova D, Barrow J, Radisky E, Edwards CQ, Griffen LM, Kushner JP. Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes. Am J Hum Genet. 1997 Jun; 60(6):1439-47.
    View PubMed
  35. Radisky ES, Ajioka RS, Edwards CQ, Griffen LM, Kushner JP. Mapping recombinant events with molecular markers in hemochromatosis pedigrees. Cytogenet Cell Genet. 1994; 67(2):126-8.
    View PubMed
  36. Radisky DC, Radisky ES, Barrows LR, Copp BR, Kramer RA, Ireland CM. Novel cytotoxic topoisomerase II inhibiting pyrroloiminoquinones from Fijian sponges of the genus Zyzzya. J Am Chem Soc. 1993; 115:1632-8.
  37. Yu Y, Radisky E, Leibold EA. The iron-responsive element binding protein. Purification cloning, and regulation in rat liver. J Biol Chem. 1992 Sep 15; 267(26):19005-10.
    View PubMed
  38. Garey JR, Harrison LM, Franklin KF, Metcalf KM, Radisky ES, Kushner JP. Uroporphyrinogen decarboxylase: a splice site mutation causes the deletion of exon 6 in multiple families with porphyria cutanea tarda. J Clin Invest. 1990 Nov; 86(5):1416-22.
    View PubMed